Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

Jan 20, 2021

Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Jan 6, 2021

Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances

Jan 5, 2021

Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021

Dec 30, 2020

Ocuphire to be Featured in Cantor Fitzgerald Fireside Chat with Equity Research Analyst Kristen Kluska

Dec 8, 2020

Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Nov 19, 2020

Ocuphire Pharma Announces Expansion of Global Patents for Nyxol® and $1.7 Million NIH Grants for APX3330 Program

Nov 16, 2020

Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program

Nov 12, 2020

Ocuphire to Participate in Upcoming Virtual HCW Conference in November

Nov 10, 2020

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Ocuphire Pharma Inc.

Nov 9, 2020